Researchers are actively investigating how to overcome resistance to CDK4/6 inhibitors. A Phase 1b trial (TAKTIC) evaluated ipatasertib, an AKT pathway inhibitor, combined with endocrine therapyTreatments that reduce or block hormones that fuel certain cancers.Click for full explanation → and palbociclib in patients with treatment-refractory HR+/HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →-negative metastatic disease. A Phase 3 trial (NCT04305496) compared capivasertib plus fulvestrant against placebo plus fulvestrant in locally advanced or metastatic HR+/HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →-negative breast cancer. In HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →-positive disease, a Phase 3 study (NCT05894239) is examining inavolisib combined with a pertuzumab-trastuzumab fixed-dose combination in PIK3CA-mutated HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →-positive metastatic breast cancer. For TNBC, a Phase 3 trial (NCT06103864) is testing datopotamab deruxtecan (Dato-DXd) with or without durvalumab against chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → plus pembrolizumab in PD-L1-positive metastatic or locally recurrent disease. Another Phase 3 study (ASCENT-05, NCT05633654) is evaluating sacituzumab govitecan plus pembrolizumab versus capecitabine for TNBC with residual invasive disease after surgery and neoadjuvant therapy. In early HR+ disease, a Phase 3b trial (NCT05827081) is examining ribociclib combined with endocrine therapyTreatments that reduce or block hormones that fuel certain cancers.Click for full explanation →. A pooled analysis from five randomized trials found that omitting axillary lymph node surgery reduces surgical morbidity without compromising survival, though it also limits staging data that determines CDK4/6 inhibitor eligibility. A Phase 3 trial (NCT06058377) is adding durvalumab to standard chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → for Stage II-III breast cancer. Novel radiopharmaceutical approaches, including lutetium-177-labeled NeoB targeting the gastrin-releasing peptide receptor combined with ribociclib and fulvestrant (NCT05870579), are in Phase 1 testing.
Where the evidence stands
CDK4/6 inhibitors combined with endocrine therapyTreatments that reduce or block hormones that fuel certain cancers.Click for full explanation → have the strongest evidence base in HR+/HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →-negative advanced breast cancer, supported by multiple Phase 3 trials and meta-analysesA statistical method that combines results from multiple studies for a stronger conclusion.Click for full explanation → confirming improvements in progression-free and overall survivalThe percentage of patients still alive after a set period — a key clinical trial endpoint.Click for full explanation →. HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →-directed therapies, particularly trastuzumab deruxtecan, have Phase 3 data in both HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →-positive and HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →-low settings. ImmunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → with pembrolizumab for TNBC is supported by Phase 3 evidence. AKT pathway inhibitors such as capivasertib are approved in select patients, while newer agents like inavolisib are in ongoing Phase 3 evaluation. Novel antibody-drug conjugates such as datopotamab deruxtecan are now in Phase 3 testing. De-escalation of axillary surgery is supported by pooled trial data, but its interaction with treatment eligibility decisions is still being worked out. Radiopharmaceutical strategies remain early-stage.
What this means for people affected
Breast cancer treatment options have expanded substantially across all major subtypes, and treatment selection depends heavily on tumor biology, molecular markers, and prior therapy history. Hormone receptor-positive disease has multiple targeted options that extend remission in advanced settings. HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →-positive disease has highly effective antibody-drug conjugates available. TNBC, historically the hardest subtype to treat, now has immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → and newer targeted agents. The active research pipeline addresses resistance to established treatments, explores ways to reduce surgical burden, and tests new drug combinations, suggesting the landscape will continue to evolve.
Last updated May 4, 2026
Recent research findings
Understanding evidence levels▼
PreclínicoLab or cell studies — no human data yet.
Estudio en animalesResults in animals only — may not apply to humans.
Ensayo Fase 1First-in-human safety testing in small groups.
Ensayo Fase 2Early effectiveness testing in a larger group.
Ensayo Fase 3Large controlled trial — the strongest trial evidence.
Estudio observacionalPatterns observed in populations — not a controlled trial.
RevisiónSummary analysis of multiple existing studies.
MetaanálisisStatistical pooling of results from multiple studies.
Estudio en animalesResultados solo en animales. Puede o no aplicarse a humanos.Published: May 22, 2026
New Biodegradable Implant Helps Doctors Locate Cancer Tumors
Researchers created a new implant made of a soft, biodegradable material that can be used to mark cancer tumors. This implant uses sound waves to create a unique signature that can be seen on ultrasound images. In lab experiments, the implant worked well and didn't cause any harm to the animals tested.
Why it matters: This finding could help doctors more accurately locate and treat breast cancer.
Early-stage research, conducted in live pig and rat experiments.
Estudio de laboratorioExperimentos de laboratorio en células o tejidos. Sin datos humanos ni animales.Published: May 22, 2026
IGF2BP3 protein linked to breast cancer spread
Researchers studied how a protein called IGF2BP3 affects breast cancer. They found that IGF2BP3 may help breast cancer spread by changing the way certain genes are expressed. This is an early finding that needs more research.
Why it matters: This study provides new insights into the biology of breast cancer and may help scientists develop new treatments in the future.
This study was conducted in a lab and has not been tested in people yet.
Estudio observacionalPatrones observados en poblaciones a lo largo del tiempo, no es un experimento controlado.Published: May 22, 2026
Rare Breast Condition Recurs Despite Surgery
Researchers reported a case of a young woman with a rare condition causing her breasts to grow abnormally large. Despite multiple surgeries, the condition recurred, causing significant distress. The researchers found that the condition was caused by benign breast tumors and abnormal growth of breast tissue.
Why it matters: This finding highlights the need for early and definitive treatment in patients with this rare condition.
Estudio de laboratorioExperimentos de laboratorio en células o tejidos. Sin datos humanos ni animales.Published: May 21, 2026
Automated Cancer Treatment Planning Improves Safety
Researchers developed a new computer program to plan cancer treatments. They tested it on 20 patients and found it reduced the dose of radiation to sensitive organs and improved the efficiency of treatment delivery.
Why it matters: This finding could lead to safer and more efficient cancer treatments for patients.
RevisiónResumen y análisis de estudios publicados existentes.Published: May 21, 2026
Using AI to Update Cancer Treatment Guidelines
Researchers used a type of artificial intelligence called a Large Language Model to compare and update cancer treatment guidelines. They found that while the AI was able to identify some changes, it also made mistakes. This suggests that while AI may be helpful in updating guidelines, it still needs to be improved.
Why it matters: This finding is important because it highlights the need for better ways to update cancer treatment guidelines to ensure that doctors have the most up-to-date information.
The study focused on breast cancer guidelines and used a specific type of AI model, which may not be applicable to other types of cancer or AI models.
Estudio de laboratorioExperimentos de laboratorio en células o tejidos. Sin datos humanos ni animales.Published: May 21, 2026
Natural Compound Shows Promise Against Breast Cancer
Researchers studied a natural compound called cycloartane triterpenoids (CATT) from the plant Dysoxylum malabaricum. They found that it can kill breast cancer cells in lab experiments and in mice with cancer. The compound may work by damaging the cells' energy-producing structures and triggering a process called apoptosis.
Why it matters: This finding could lead to the development of new treatments for breast cancer.
Efficacy
CATT exhibited potent cytotoxicity against T-47D cells (IC = 40 µg/ml) while sparing normal cells (IC > 80 µg/ml).
The study was conducted in lab experiments and in mice, so it's not clear if the results will translate to humans.
Estudio observacionalPatrones observados en poblaciones a lo largo del tiempo, no es un experimento controlado.Published: May 21, 2026
AI Helps Predict Cancer Outcomes Based on Socioeconomic Status
Researchers used artificial intelligence to analyze how socioeconomic status affects cancer outcomes. They compared this approach to traditional methods and found that it worked better in predicting survival rates for certain types of cancer. However, more research is needed to confirm these findings.
Why it matters: This study could help doctors better understand how socioeconomic factors impact cancer outcomes and potentially lead to more personalized treatment plans.
Efficacy
The largest improvement in overall survival prediction was observed in thyroid carcinoma (c-index +6.85%, from 0.555 to 0.593), followed by breast cancer (4.46%) and lung cancer (2.19%).
Estudio observacionalPatrones observados en poblaciones a lo largo del tiempo, no es un experimento controlado.Published: May 21, 2026
Personalized Breast Cancer Care Tool Developed
Researchers created a tool called COMPASS to help breast cancer patients and doctors make treatment decisions. The tool is integrated into electronic health records and patient portals. It was designed to address challenges faced by patients and clinicians.
Why it matters: This finding could improve the care experience for breast cancer patients by providing personalized support.
✦ Hallazgo significativoUna señal relevante de investigación en etapas avanzadas, o un resultado sólido de fase 2 que destaca frente a hallazgos habituales.MetaanálisisAnálisis estadístico agrupado de resultados de múltiples estudios.Published: May 21, 2026
Combining chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → with immune checkpoint inhibitors for early triple-negative breast cancer
Researchers compared chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → with or without immune checkpoint inhibitors in people with early-stage triple-negative breast cancer. They found that adding these inhibitors may improve cancer response and survival, but also increases the risk of certain side effects. However, the benefits may be limited to patients who receive treatment before surgery.
Why it matters: This finding could help doctors decide whether to add immune checkpoint inhibitors to chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → for patients with early-stage triple-negative breast cancer.
Efficacy
PD-1 or PD-L1 inhibitors plus chemotherapy probably increase pathological complete response rate (RR 1.47, 95% CI 1.15 to 1.86); improve event-free survival (HR 0.64, 95% CI 0.52 to 0.79); and probably improve overall survival (HR 0.56, 95% CI 0.34 to 0.93) compared with chemotherapy alone.
Seven randomized controlled trials with a total of 4341 participants were included in the analysis, but two of these trials were at high risk of bias due to lack of blinding.
RevisiónResumen y análisis de estudios publicados existentes.Published: May 21, 2026
Targeted Exosomes May Improve Breast Cancer Treatment
Researchers looked at how targeted exosomes, tiny particles that can carry medicine, might help deliver cancer drugs to breast cancer cells. They reviewed existing studies on exosomes and their potential to improve treatment. The results suggest that targeted exosomes could be useful, but more research is needed.
Why it matters: This finding could lead to new ways to treat breast cancer, but more research is required to make it a reality.
The review is based on existing studies, and more research is needed to confirm the findings.
Estudio de laboratorioExperimentos de laboratorio en células o tejidos. Sin datos humanos ni animales.Published: May 21, 2026
MRI Image Analysis Improves Breast Tissue Segmentation
Researchers compared three methods for analyzing MRI images of breast tissue to improve accuracy. They found that a standard method worked best, but two other methods were comparable. The study used 136 MRI images to test the methods.
Why it matters: This finding could help improve the accuracy of MRI analysis for breast tissue, which is important for medical imaging and research.
Estudio observacionalPatrones observados en poblaciones a lo largo del tiempo, no es un experimento controlado.Published: May 21, 2026
Predicting Breast Cancer Treatment Response with PET Scans
Researchers used PET scans to predict how well breast cancer patients would respond to treatment. They found that the extent of cancer in the axillary lymph nodes before treatment was a good predictor of treatment success. However, more extensive cancer in these nodes was associated with lower chances of complete treatment response.
Why it matters: This finding could help doctors decide how to manage the axillary lymph nodes in breast cancer patients, potentially improving treatment outcomes.
Efficacy
Discrimination was good: AUC 0.80 (95% CI 0.72-0.88) for Model A and 0.79 (95% CI 0.71-0.87) for Model B.
Single-center retrospective cohort with 115 patients.
Endocrine TherapyTreatments that reduce or block hormones that fuel certain cancers.Click for full explanation → Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation → Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Evolutionary Clinical TrialA research study that tests a medical intervention in human volunteers.Click for full explanation → for Novel BiomarkerA measurable biological signal used to detect disease or predict treatment response.Click for full explanation →-Driven Therapies
Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men With Node-positive and High-risk Node-negative Invasive Breast Cancer
Adding an ImmunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → Drug, MEDI4736 (Durvalumab), to the Usual ChemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
